A Phase 3 interventional study of Alirocumab and Placebo for alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 62 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 8th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 31st registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 615 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 9th largest by enrollment, is one of 4 that started in 2016, is one of 22 in phase 3, and was the 31st registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison to ezetimibe 10 mg daily after 24 weeks of treatment in Asia in participants with hypercholesterolemia at high cardiovascular (CV) risk.
Secondary Objectives:
The maximum study duration was 35 weeks per participant, which included a screening period of up to 3 weeks, a 24-week randomized treatment period, and an 8-week post-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin at a stable dose for at least 4 weeks prior to the screening visit (Week -3).
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
Drug: Placebo for alirocumab · Drug: ezetimibe · Drug: atorvastatin · Drug: rosuvastatin · Drug: simvastatin
Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was \>=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter \[mmol/L\]) at Week 8.
Drug: Alirocumab · Drug: placebo for ezetimibe · Drug: atorvastatin · Drug: rosuvastatin · Drug: simvastatin
Pharmaceutical form:solution Route of administration: subcutaneous
Also known as: SAR236553 (REGN727)
Pharmaceutical form:solution Route of administration: subcutaneous
Pharmaceutical form:capsule Route of administration: oral
Pharmaceutical form:capsule Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis
Adjusted least square (LS) means and standard errors at Week 24 were obtained from mixed models analysis with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 up to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis
Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis
Adjusted percentages at Week 24 were obtained from multiple imputation approach including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis
Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
Time frame: From Baseline to Week 24
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis
Adjusted means and standard errors at Week 24 were obtained by using multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis
Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis
Adjusted means and standard errors at Week 12 were obtained by using multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
The study was conducted at 61 centers in China, India and Thailand. Overall 1163 participants were screened between 27 July 2016 and 18 December 2017, of whom 548 were screen failures. Screen failures were mainly due to exclusion criteria met. A total of 615 participants were randomized in 2:1 ratio to alirocumab: ezetimibe.
| Milestone | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Started | 208 | 407 |
| Treated | 207 | 405 |
| Safety population | 206 | 406 |
| Completed | 190 | 380 |
| Not completed | 18 | 27 |
| Withdrew: Adverse event | 2 | 6 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Participant moved | 1 | 3 |
| Withdrew: Other than specified above | 11 | 15 |
| Withdrew: Randomized but not treated | 1 | 2 |
Adjusted least square (LS) means and standard errors at Week 24 were obtained from mixed models analysis with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis | -20.3 ± 2.0 | -56.0 ± 1.5 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis | -21.3 ± 2.0 | -58.7 ± 1.4 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis | -22.2 ± 1.9 | -57.1 ± 1.4 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis | -22.7 ± 1.9 | -58.1 ± 1.4 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis | -16.2 ± 1.4 | -43.5 ± 1.0 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis | -17.4 ± 1.4 | -45.2 ± 1.0 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis | -19.4 ± 1.7 | -47.0 ± 1.2 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis | -20.4 ± 1.7 | -49.1 ± 1.2 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 up to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis | -13.8 ± 1.2 | -33.9 ± 0.9 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis | -16.5 ± 1.4 | -43.0 ± 1.0 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis | -20.7 ± 1.6 | -47.4 ± 1.1 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis | -14.9 ± 1.2 | -34.2 ± 0.8 |
Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
| percentage of participants | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis | 40.5 | 85.1 |
Adjusted percentages at Week 24 were obtained from multiple imputation approach including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percentage of participants | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis | 42.1 | 87.0 |
Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis | 3.956 ± 2.095 | -30.317 ± 1.461 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis | 6.5 ± 1.3 | 8.3 ± 0.9 |
Adjusted means and standard errors at Week 24 were obtained by using multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis | -14.409 ± 1.904 | -14.462 ± 1.341 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis | -0.2 ± 0.8 | 3.2 ± 0.6 |
Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent Change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis | 6.313 ± 2.056 | -30.064 ± 1.449 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis | 6.1 ± 1.2 | 7.3 ± 0.9 |
Adjusted means and standard errors at Week 12 were obtained by using multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis | -13.585 ± 1.929 | -9.965 ± 1.379 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis | 1.1 ± 0.8 | 3.7 ± 0.6 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 32 weeks of the study regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe 10 mg | 3/206 (1.5%) | 23/206 (11.2%) | 41/206 (19.9%) |
| Alirocumab 75 mg Q2W/up150 mg Q2W | 2/406 (0.5%) | 41/406 (10.1%) | 71/406 (17.5%) |
| Event | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up150 mg Q2W |
|---|---|---|
| Angina UnstableCardiac disorders | 0/206 | 9/406 |
| Acute Myocardial InfarctionCardiac disorders | 3/206 | 3/406 |
| PneumoniaInfections and infestations | 0/206 | 4/406 |
| Cardiac Failure CongestiveCardiac disorders | 2/206 | 0/406 |
| DeathGeneral disorders | 2/206 | 0/406 |
| Ischaemic StrokeNervous system disorders | 2/206 | 0/406 |
| Arteriosclerosis Coronary ArteryCardiac disorders | 1/206 | 2/406 |
| Cardiac FailureCardiac disorders | 1/206 | 2/406 |
| BronchitisInfections and infestations | 0/206 | 2/406 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 0/206 | 2/406 |
| Event | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up150 mg Q2W |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 29/206 | 54/406 |
| Accidental OverdoseInjury, poisoning and procedural complications | 15/206 | 27/406 |
Analysis was performed on randomized participants.
| Age, Continuous(Years) | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 58.3 ± 11.2 | 58.8 ± 10.7 | 58.6 ± 10.8 |
| Sex: Female, Male(Participants) | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Total |
|---|---|---|---|
| Female | 62 | 92 | 154 |
| Male | 146 | 315 | 461 |
| Race (NIH/OMB)(Participants) | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 208 | 407 | 615 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Calculated LDL-C in mmol/L(mmol/L) | Ezetimibe 10 mg | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 2.875 ± 1.287 | 2.862 ± 1.253 | 2.866 ± 1.264 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Aug 2018, 24 months.
Results were first posted in Sep 2019, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab